CRISPR THERAPEUTICS AG

NASDAQ: CRSP (CRISPR Therapeutics AG)

最近更新时间: 5小时之前

40.15

-0.22 (-0.54%)

前收盘价格 40.37
成交量 4,108,033
价格/销量 (P/S) 174.15
股市价格/股市净资产 (P/B) 2.48
52周波幅
39.80 (-0%) — 63.45 (58%)
营业利益率 (TTM) -17,158.84%
稀释每股收益 (EPS TTM) -4.49
季度收入增长率 (YOY) 71.60%
总债务/股东权益 (D/E MRQ) 11.99%
流动比率 (MRQ) 15.64
营业现金流 (OCF TTM) -306.47 M
杠杆自由现金流 (LFCF TTM) -193.24 M
资产报酬率 (ROA TTM) -12.88%
股东权益报酬率 (ROE TTM) -19.71%

AIStockmoo 评分

-0.7
价值 30% -0.9
来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 NA
相对估值 参考 NA
隐含增长 参考 NA
历史估值 参考 NA
负债低。盈利能力弱。短期流动性充足。现金流为负。 参考
资本回报低于资本成本。资本回报上升。 参考
时机 30% -1.7
来自我们对走势图的 AI 技术分析。 参考 NA
过去一年没有明确趋势。股价远低于52周高点。 参考
K线形态 参考 NA
您持有期的趋势 参考 NA
市场情绪 20% 0.4
近期没有目标价,因此依据目标价的调整方向。 参考
近期新闻大多正面。 参考
聪明钱 20% 0.6
内部交易活动 参考 NA
机构在最新13F申报中净+0.42%的股份:251家增持,209家减持(截至30 Sep 2026的季度)。 参考
空头持仓从31 Aug到30 Oct 2026变化-8.4%,回补天数13.1天(FINRA)。 参考
市场和行业状况不佳。
市场环境偏谨慎。 参考
行业表现落后大市。
各支柱方向一致,评分因此加强。
不计入评分
股价低于其52周平均水平。5年来下跌。 参考
短、中、长期趋势均向下。短期动能下降。 参考
支撑与阻力水平趋降。 参考
最终评分 -0.66

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 看涨
Biotechnology (全球的) 混合的 看涨
股票 CRISPR Therapeutics AG 混合的 看跌

相关股票

股票 市值 DY P/E(TTM) P/B
CRSP - - - 2.48
GMAB - - - 4.99
REGN - 0.39% - 2.95
ABVX - - - 16.72
FOLD 5 B - - -
IGMS 71 M - - 0.760

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

部门 Healthcare
行业 Biotechnology
投资方式 Mid Value
内部持股比例 1.69%
机构持股比例 76.46%

所有权

姓名 日期 持有股份
Ark Investment Management Llc 30 Sep 2026 10,056,844
Orbis Allan Gray Ltd 30 Sep 2026 4,519,261
Gsk Plc 30 Sep 2026 2,608,419
Sumitomo Mitsui Trust Group, Inc. 30 Sep 2026 1,453,713
Amova Asset Management Americas, Inc. 30 Sep 2026 1,453,513

该时间范围内无数据。

机构

机构持股比例: 81.86%

持仓变动 机构数 股数
增持 251 6,196,285
减持 209 6,222,834
新建仓 65 826,959
清仓 67 394,972

来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。

空头持仓

结算日 股数 回补天数
30 Oct 2026 17,189,067 13.1
15 Oct 2026 16,442,415 10.2
30 Sep 2026 18,679,198 9.6
15 Sep 2026 19,071,093 16.5
31 Aug 2026 18,769,995 10.7
14 Aug 2026 18,744,855 15.6

来源:经Nasdaq的FINRA空头持仓数据,每月公布两次。

8 正面 3 负面 8 中性
日期 类型 细节
17 Nov 2026 Yahoo Finance CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
17 Nov 2026 Yahoo Finance CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
CRISPR Therapeutics (NASDAQ:CRSP) is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy programs and growing demand for its commercial product, CASGEVY. CEO Sam Kulkarni said during a Jeff…
10 Nov 2026 Yahoo Finance CRISPR Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
ZUG, Switzerland and BOSTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 10:00 a.m. GMT. A live…
09 Nov 2026 Yahoo Finance CRISPR Therapeutics Presents Phase 1b Data for CTX310® Demonstrating Reductions in ANGPTL3 and Triglycerides in Patients with Severe Hypertriglyceridemia at the American Heart Association (AHA) Scientific Sessions 2026
-Data presented in a late-breaking oral presentation at AHA- -A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG), who had a median baseline TG level…
08 Nov 2026 Yahoo Finance CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases
Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all responders maintaining response Zugo-cel has been well tolerated in all 21 patients dosed to date, with no…
06 Nov 2026 Yahoo Finance CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
04 Nov 2026 Yahoo Finance CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition
ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from the ongoing Phase 1/2 trial of zugocabtagene geleucel (zugo-cel), its investigational allogeneic…
03 Nov 2026 Yahoo Finance Vertex Slumps On Light Pain Drug Sales, But A Key Kidney Catalyst Lies Ahead
Vertex stock slumped Tuesday despite notching a definitive beat for its Crispr-partnered blood diseases gene editor, Casgevy.
03 Nov 2026 Yahoo Finance Why Did CRISPR Therapeutics (CRSP) Stock Slide After Its Latest Update?
CRISPR Therapeutics (CRSP) has released its third quarter 2026 results, reporting revenue of US$12.67 million and a net loss of US$111.44 million, providing investors with updated financial data to review. The latest quarterly update and pipeline news landed against a backdrop where CRISPR…
03 Nov 2026 Yahoo Finance CRISPR Therapeutics (CRSP) Stock Looks Fully Valued As It Names A New CTO
CRISPR Therapeutics has been a volatile ride for shareholders, and the latest moves raise a straightforward question for anyone looking at the stock today. Is the current share price meaningfully supported by what sits on its balance sheet in terms of book value, or is the market asking you to pay…
03 Nov 2026 Yahoo Finance CRISPR Therapeutics (CRSP) Appoints Siva Sakhamuri As Chief Technical Officer
CRISPR Therapeutics (NasdaqGM:CRSP) appointed Siva Sakhamuri, Ph.D., as Chief Technical Officer, according to a recent company announcement. Dr. Sakhamuri brings experience leading technical operations and manufacturing functions at established biotechnology enterprises focused on complex…
03 Nov 2026 Yahoo Finance Crispr Therapeutics Reports Growing Casgevy Use Ahead of Key Pipeline Data, RBC Says
Crispr Therapeutics (CRSP) is seeing continued growth in the use of its gene-editing treatment Casge…
03 Nov 2026 Yahoo Finance CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates
CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
03 Nov 2026 Yahoo Finance VRTX's Q3 Earnings Lag Estimates, Revenues Top, 2026 Sales View Raised
Vertex misses Q3 earnings estimates but beats revenue expectations, driven by CF drug sales and growth in Casgevy and Journavx, prompting a 2026 sales outlook hike.
02 Nov 2026 Yahoo Finance CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates
CRISPR Therapeutics (CRSP) delivered earnings and revenue surprises of -8.49% and +27.39%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
02 Nov 2026 Yahoo Finance Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction
CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.
02 Nov 2026 Yahoo Finance CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age and older with severe SCD or TDT, and in the United Arab Emirates and Bahrain for children 2 years…
02 Nov 2026 Yahoo Finance CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
02 Nov 2026 Yahoo Finance CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer
ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing…
30 Oct 2026 Yahoo Finance Here's Why CRISPR Therapeutics AG (CRSP) Fell More Than Broader Market
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $51.36, moving 5.34% from the previous trading session.
显示更多

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票